Jacobs Levy Equity Management
FHTX icon

Jacobs Levy Equity Management’s Foghorn Therapeutics FHTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Buy
305,434
+1,677
+0.6% +$7.44K 0.01% 649
2026
Q1 		$1.45M Buy
303,757
+34,571
+13% +$190K 0.01% 646
2025
Q4 		$1.45M Buy
269,186
+85,123
+46% +$386K 0.01% 631
2025
Q3 		$900K Sell
184,063
-8,600
-4% -$45.6K ﹤0.01% 738
2025
Q2 		$906K Sell
192,663
-49,153
-20% -$205K ﹤0.01% 773
2025
Q1 		$883K Buy
241,816
+18,036
+8% +$82.2K ﹤0.01% 830
2024
Q4 		$1.06M Buy
223,780
+94,449
+73% +$688K ﹤0.01% 707
2024
Q3 		$1.2M Sell
129,331
-54,973
-30% -$398K ﹤0.01% 692
2024
Q2 		$1.06M Sell
184,304
-31,966
-15% -$190K ﹤0.01% 728
2024
Q1 		$1.45M Buy
216,270
+108,700
+101% +$603K 0.01% 647
2023
Q4 		$694K Buy
107,570
+58,704
+120% +$253K ﹤0.01% 783
2023
Q3 		$244K Sell
48,866
-6,988
-13% -$53.9K ﹤0.01% 899
2023
Q2 		$393K Sell
55,854
-74,993
-57% -$524K ﹤0.01% 851
2023
Q1 		$811K Buy
+130,847
New +$856K 0.01% 738

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Jacobs Levy Equity Management's FHTX Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Foghorn Therapeutics (FHTX) stake by 0.55% in Q2 2026, buying an estimated $7.44K and bringing the position to 305,434 shares worth $1.49M. The position accounts for 0.01% of the portfolio, ranked #649.

Jacobs Levy Equity Management first reported a position in FHTX in Q1 2023 and has held it in 14 quarters since. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Jacobs Levy Equity Management held 305,434 shares of Foghorn Therapeutics worth $1.49M as of Q2 2026.
  • Jacobs Levy Equity Management bought 1,677 Foghorn Therapeutics shares in Q2 2026, an estimated $7.44K.
  • Foghorn Therapeutics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #649 holding.
  • Jacobs Levy Equity Management first reported a position in Foghorn Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.